Cost Calculation and Adherence to ADA Recommendations Based on a Flash Continuous Glucose Monitoring System for People with T1DM or T2DM Using MDI Therapy

Background: A novel, factory-calibrated, flash continuous glucose monitoring system (flash CGM; FreeStyle Libre™ system) was approved by FDA in September 2017. The clinical benefit of flash CGM as a replacement for routine self-monitoring of blood glucose (SMBG) for people using MDI therapy has been assessed in RCTs in T1DM (Bolinder, 2016) and T2DM (Haak,2017). In both 6-month studies, people using flash CGM achieved a substantial reduction in hypoglycemia compared with those using SMBG, without increasing HbA1c or reducing the dose of insulin.”

Source: Cost Calculation and Adherence to ADA Recommendations Based on a Flash Continuous Glucose Monitoring System for People with T1DM or T2DM Using MDI Therapy